Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

153.67 -2.48 (-1.59%)
Official Closing Price Updated: 4:10 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
58 59 Next >
News headline image
FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors ↗
Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by... 
Via Benzinga
News headline image
Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday? ↗
Stocks surged as weak economic data raised hopes for Fed rate cut. S&P 500 up 1.2%, Nasdaq 100 up 1.5%, Dow Jones up 0.6%. Spotify shares jump 17% on earnings. 
Via Benzinga
Topics Economy Stocks
News headline image
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024 ↗
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise ↗
Shares have risen markedly over the past two days and gained again Tuesday. 
Via Investor's Business Daily
News headline image
Looking At Novartis's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
News headline image
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates ↗
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for... 
Via Talk Markets
News headline image
What's Going On With Pfizer Stock On Thursday? ↗
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
Via Benzinga
Topics Intellectual Property
News headline image
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
News headline image
Why Novartis Stock Topped the Market on Tuesday ↗
A double beat on the latest quarterly results and raised guidance made investors happy. 
Via The Motley Fool
News headline image
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript ↗
NVS earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook ↗
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth. 
Via Benzinga
News headline image
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback' ↗
The mood on Wall Street turned tentative on Tuesday as investors awaited earnings reports from the “Magnificent 7,” companies that fueled much of the market’s upside since 2023. Index futures rose... 
Via Benzinga
Topics Bonds
News headline image
Top Analyst Reports For Novartis, American Express & ConocoPhillips ↗
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), American Express Company (AXP) and ConocoPhillips (COP). 
Via Talk Markets
News headline image
The Bad News Heading Into AbbVie's First-Quarter Earnings Report ↗
AbbVie is working against numerous biosimilar versions of Humira. But one has "stepped up dramatically." 
Via Investor's Business Daily
News headline image
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
News headline image
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years ↗
Sustained efficacy with Novartis' Kesimpta for up to 6 years in recently diagnosed relapsing multiple sclerosis. Significant reductions in relapses, MRI lesions, and disability worsening observed. 
Via Benzinga
News headline image
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years ↗
These income stocks look like good options at current levels. 
Via The Motley Fool
News headline image
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
News headline image
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades ↗
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction. 
Via Benzinga
News headline image
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%. ↗
Think globally with this high-yielding ETF. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
News headline image
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
News headline image
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday? ↗
Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities. 
Via Benzinga
News headline image
SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today ↗
SoundHound AI stock is falling on Wednesday as investors in SOUN are worried about the company's plans for a secondary offering. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost ↗
Alibaba stock is up on Wednesday as investors in BABA react to positive comments from cofounder Jack Ma concerning its leadership team. 
Via InvestorPlace
News headline image
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts ↗
Novartis layoffs will see the healthcare company cut 680 jobs in the U.S. and Switzerland over the next two to three years. 
Via InvestorPlace
Topics Workforce
News headline image
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says ↗
Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho... 
Via Benzinga
News headline image
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report ↗
Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.